MeiraGTx Deal History & Licensing Activity
MeiraGTx is a biotech headquartered in US. Over the past three years, MeiraGTx has been involved in 8 licensing and acquisition transactions, with a primary focus on Gene Therapy (10 deals). The company currently has 7 active clinical trials, primarily in Ophthalmology.
Deals (12mo)
4
Active Trials
7
Top Modality
Gene Therapy
Focus Area
Ophthalmology
MeiraGTx Recent Deal Activity
Licensing, acquisition, and partnership transactions involving MeiraGTx in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| botaretigene sparoparvovec (bota-vec) | Johnson & Johnson | Gene Therapy | Phase 3 | acquisition | Apr 16, 2026 |
| botaretigene sparoparvovec | MeiraGTx Holdings plc | Gene Therapy | Phase 3 | acquisition | Apr 15, 2026 |
| AI-designed therapies for geographic atrophy | ZipBio | Other | Unknown | license | Feb 3, 2026 |
| AAV-AIPL1 | Eli Lilly and Company | Gene Therapy | Preclinical | collaboration | Nov 10, 2025 |
MeiraGTx Pipeline Focus
Therapeutic areas and modalities where MeiraGTx is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
MeiraGTx Strategic Signals
Key indicators of MeiraGTx's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
MeiraGTx Clinical Pipeline
MeiraGTx has 7 active clinical trials across 3 development phases.
3
Unknown
2
Phase 1/2
2
Phase 2
See How Your Asset Matches MeiraGTx's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Ophthalmology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Ophthalmology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for ophthalmology
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About MeiraGTx Licensing & Deal Activity
MeiraGTx is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 8 deals over the past three years, MeiraGTx ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for MeiraGTx include Ophthalmology (11 deals and trials), Hematological Malignancies (2 deals and trials), Neurology (1 deal and trial), and CNS Disorders (1 deal and trial). In terms of modality, MeiraGTx has shown particular interest in gene therapy, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for MeiraGTx and 700+ other biopharma companies. Use our Solidus to benchmark your asset against MeiraGTx's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.